Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.

Lord, Christopher J

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. [electronic resource] - Annual review of medicine 2015 - 455-70 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

1545-326X

10.1146/annurev-med-050913-022545 doi


Benzamides--therapeutic use
Breast Neoplasms--drug therapy
Drug Resistance, Neoplasm
Enzyme Inhibitors--therapeutic use
Female
Genes, BRCA1
Genes, BRCA2
Humans
Mutation
Neoplasms--drug therapy
Neoplasms, Cystic, Mucinous, and Serous--drug therapy
Ovarian Neoplasms--drug therapy
Phthalazines--therapeutic use
Piperazines--therapeutic use
Poly (ADP-Ribose) Polymerase-1
Poly(ADP-ribose) Polymerase Inhibitors